
|Videos|July 26, 2017
Recurrent Metastatic Gastrointestinal Stromal Tumor
Recurrent Metastatic Gastrointestinal Stromal Tumor
Advertisement
September 2014
- A 64-year old Caucasian male presented with abdominal pain and 3-month history of fatigue
- PMH was remarkable for hypertension well-controlled with a beta-blocker
- No family history of cancer
- He could perform all activities independently
- Abdominal CT findings:
- 12-cm mass arising from the stomach and involving the cardia, fundus, and body of the stomach
- 7-cm solitary mass in the left lobe of the liver
- Biopsy results:
- Gastric GIST with liver metastases
- IHC positive for CD117 (c-KIT), molecular analysis showed exon 9 deletion
- Mitotic activity, high with >5 mitoses/50 HPFs
- Treatment was initiated with neoadjuvant imatinib 600 mg daily for 5 months
- The primary tumor was stable during this time, the liver mass size decreased from 7 cm to 4 cm
- The patient was referred to a surgeon and underwent hepatectomy for the liver metastasis
- Following surgery, R0 resection with clear margins
- Treatment was initiated with imatinib 800 mg daily
August 2016
- Abdominal CT imaging findings:
- Multiple peritoneal implants
- A new small nodule (<1 cm) in the liver
- The patient could perform all activities independently with small occasional breaks, but could not perform physically strenuous activities
- He was switched to sunitinib 37.5 mg daily
February 2017
- At his 6-month follow-up, the patient was still able to perform most non-strenuous activities independently; however, the frequency of being able to do so had declined significantly
- Abdominal CT scan showed progression in multiple peritoneal implants; the liver nodule increased in size to 2 cm
- He was referred to an academic center
- His treatment was switched to regorafenib 160 mg, 3 weeks on, 1 week off
- The patient appeared to tolerate therapy well, after initial dose modification due to diarrhea experienced during the second week of therapy
- At the 6-month follow-up:
- Abdominal CT scan showed slight reduction in the peritoneal implants
- The liver nodule was no longer visible
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































